We have changed our visitation policy for the safety of our patients and staff. Click here for the updated visitation policy and click here for information about COVID-19.

[LCID Study Number: 2001-040]

Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS)

The purpose of this study is to make 3,4-DAP available to patients with LEMS or CMS who are either inadequately responsive to or intolerant of other available therapies, or for whom 3,4-DAP provides a better risk-benefit than currently available therapies, in the opinion of the principal investigator

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-8256